Somatostatin analogs
Synthetic analogs of the hormone somatostatin (e.g. octreotide, lanreotide, pasireotide). They activate somatostatin receptors (SSTR2/5; pasireotide more broadly) and suppress the release of growth hormone, insulin, glucagon and gastrointestinal hormones — used in acromegaly and neuroendocrine tumours.
Peptides on this topic
3 peptides researched for this topicLanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours.
- Human RCTLowers elevated growth-hormone and IGF-1 levels in acromegaly.
Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours.
- Human RCTReduction in GH and IGF-1 levels in acromegaly patients documented in randomised trials
Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly.
- Human RCTIn a phase 3 trial, lowers cortisol (urinary free cortisol) in Cushing's disease.